

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (currently amended) A pharmaceutical composition comprising an agent effective to elicit an immunogenic response to alpha-synuclein and an adjuvant that is pharmaceutically effective for human administration, wherein the adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, alum, CpG, GM-CSF and M-CSF.

2. (original) The pharmaceutical composition of claim 1, wherein the agent is alpha-synuclein or an immunogenic fragment thereof.

3. (original) The pharmaceutical composition of claim 2, wherein the agent is alpha-synuclein.

4. (original) The pharmaceutical composition of claim 2, wherein the agent is immunogenic alpha-synuclein fragment.

5. (original) The pharmaceutical composition of claim 4, wherein the agent is NAC.

6. (original) The pharmaceutical composition of any one of claims 1-5, wherein the agent is linked to a carrier molecule to form a conjugate.

7-8. (cancel)

9. (currently amended) A pharmaceutical composition comprising an agent effective to elicit an immunogenic response against an alpha-synuclein component of an amyloid plaque in a patient and an adjuvant that is pharmaceutically acceptable for human administration

wherein the adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, alum, CpG, GM-CSF and M-CSF.

10. (original) The pharmaceutical composition of claim 9, wherein the agent is alpha-synuclein or an immunogenic alpha-synuclein fragment.

11. (original) The pharmaceutical composition of claim 9, wherein the agent is alpha-synuclein.

12. (original) The pharmaceutical composition of claim 9, wherein the agent is an immunogenic alpha-synuclein fragment.

13. (original) The pharmaceutical composition of claim 12, wherein the immunogenic alpha-synuclein fragment is NAC.

14. (cancel)

15-53 (cancel)